Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.40M | 12.50M | 11.13M | 10.54M | 11.63M | 18.85M |
| Gross Profit | 7.68M | 7.91M | 7.10M | 5.32M | 4.46M | 8.60M |
| EBITDA | -6.08M | -4.63M | -5.44M | -4.93M | -25.67M | -10.69M |
| Net Income | -7.18M | -7.18M | -8.59M | -8.97M | -45.72M | -15.03M |
Balance Sheet | ||||||
| Total Assets | 20.81M | 20.81M | 26.84M | 25.42M | 36.94M | 97.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 1.96M | 6.48M | 3.02M | 7.98M | 44.89M |
| Total Debt | 6.99M | 6.99M | 8.06M | 9.79M | 7.19M | 7.96M |
| Total Liabilities | 14.65M | 14.65M | 19.73M | 15.92M | 19.05M | 39.71M |
| Stockholders Equity | 6.16M | 6.16M | 7.11M | 9.50M | 17.89M | 58.28M |
Cash Flow | ||||||
| Free Cash Flow | -9.39M | -9.39M | 848.00K | -9.79M | -22.39M | -16.77M |
| Operating Cash Flow | -9.33M | -9.33M | 946.00K | -9.64M | -18.04M | -10.89M |
| Investing Cash Flow | -53.00K | -53.00K | -98.00K | 4.31M | -4.36M | -8.33M |
| Financing Cash Flow | 5.28M | 5.28M | 2.63M | 652.00K | -10.92M | 63.27M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$34.21M | -4.70 | -97.79% | ― | ― | 23.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$141.69M | ― | -111.23% | ― | 12.96% | 40.81% | |
48 Neutral | AU$72.68M | -3.54 | -36.16% | ― | 62.81% | 16.37% | |
44 Neutral | AU$27.68M | -6.59 | -501.54% | ― | ― | 56.42% | |
43 Neutral | AU$47.50M | -2.34 | -40.54% | ― | 29.60% | 33.00% | |
38 Underperform | AU$49.96M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics Holdings Ltd. has announced the issuance of 6,007,000 performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 1,323,875 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 31, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially expand its market presence, impacting its operations and positioning within the healthcare diagnostics industry.
Lumos Diagnostics Holdings Ltd has announced a change in the director’s interest, with Doug Ward acquiring 22,000,000 performance rights. This change, approved by shareholders at the company’s 2025 Annual General Meeting, reflects a strategic move to align the interests of the director with the company’s growth objectives, potentially impacting the company’s operations and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the issuance of 22 million unquoted performance rights as part of an employee incentive scheme. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
Lumos Diagnostics has announced the adoption of a revised Constitution, as approved by shareholders at their 2025 Annual General Meeting. This update is part of the company’s ongoing efforts to align its governance framework with current operational and strategic needs, potentially impacting its operational efficiency and stakeholder engagement.
Study Overview: The FebriDx® Pediatric Validation Study, officially titled the FebriDx® Pediatric Validation Study Protocol, aims to assess the performance of the FebriDx® test in distinguishing between bacterial and non-bacterial causes of fever in children aged 2-11 years. This study is significant as it targets acute respiratory infections (ARIs) in pediatric patients, a common and challenging issue in emergency and primary care settings.
Lumos Diagnostics Holdings Ltd. announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of a director, approval of performance rights, and ratification of share issues. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic initiatives.
Lumos Diagnostics Holdings Ltd. recently held its Annual General Meeting, where the CEO presented key updates about the company’s operations and strategic direction. The presentation emphasized the company’s commitment to advancing its diagnostic solutions and highlighted the challenges and opportunities in the market. While the document provided valuable insights into Lumos’ market positioning and future plans, it also contained disclaimers about forward-looking statements, advising stakeholders to consider the inherent risks and uncertainties.
Lumos Diagnostics has made significant strides in FY25, transitioning from an early-stage business to an emerging global diagnostics company. The company has expanded its distribution partnerships, notably with Henry Schein and PHASE Scientific, and has secured reimbursement for FebriDx on the U.S. Medicare fee schedule. A successful CLIA waiver trial for FebriDx has been completed, with the application submitted to the FDA, potentially expanding the U.S. market significantly. A new distribution agreement with PHASE Scientific could be worth up to US$317 million, marking a major milestone for Lumos. The company remains well-funded, with a focus on disciplined execution and expanding its product’s clinical use, supported by BARDA.
Lumos Diagnostics reported a steady revenue of US$3.4 million for the first quarter of FY26, with a notable 300% increase in product revenue driven by the adoption of FebriDx® in the U.S. The company secured a significant distribution agreement with PHASE Scientific and is awaiting feedback on a CLIA waiver submission for FebriDx. Lumos also continues its development projects, including an expanded agreement with Hologic for a next-generation diagnostic product, and has secured a loan facility to support its working capital needs.
Lumos Diagnostics Holdings Ltd has initiated a pediatric study for its FebriDx® device in the United States, targeting children aged 2 to 12 years. This study, supported by BARDA with significant funding, aims to expand the device’s usage to differentiate bacterial from non-bacterial acute respiratory infections in younger children, potentially increasing Lumos’ market reach significantly if successful.
Lumos Diagnostics has entered into an agreement with WellStreet Urgent Care to advance the use of its FebriDx® testing through a joint venture with Piedmont Healthcare in Atlanta, Georgia. The program, set to begin in October 2025, will involve WellStreet procuring and submitting reimbursement claims for each test, with PHASE Scientific leading distribution and Pro-spectus managing billing data. The collaboration aims to provide operational insights and establish future coverage policies with national insurance organizations. If a CLIA waiver is granted, the initiative could expand to approximately 140 WellStreet locations across the US, enhancing Lumos’ market presence and operational scalability.
Lumos Diagnostics has issued an addendum to its Notice of Annual General Meeting, addressing shareholder queries regarding the timing and vesting conditions of performance rights for its CEO, Douglas Ward. The addendum does not alter the validity of previously submitted proxy votes and provides shareholders with additional details to consider before the meeting on October 24, 2025.
Lumos Diagnostics has released real-world data on its FebriDx® test, presented at the Primary Care Respiratory Society Annual Conference. The data highlights the test’s effectiveness in reducing antibiotic prescriptions, improving patient experiences, and generating significant cost savings for healthcare systems by distinguishing between viral and bacterial infections. This development underscores the potential of FebriDx® to enhance clinical decision-making, address antimicrobial resistance, and optimize healthcare resource utilization.
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, announced its participation in the ASX SMIDcaps 2025 Conference, where its CFO, Barrie Lambert, will deliver a presentation. This engagement highlights Lumos’ active role in the diagnostics industry and its commitment to advancing healthcare solutions, potentially enhancing its market presence and stakeholder relations.
Lumos Diagnostics Holdings Ltd. has announced its Annual General Meeting (AGM) will be held virtually on October 24, 2025, via a Zoom webinar. Shareholders are encouraged to register in advance and submit their proxy forms early. The virtual format allows shareholders to participate in discussions and vote on resolutions, ensuring continued engagement despite potential disruptions.
Lumos Diagnostics Holdings Ltd has issued a total of 10,193,868 fully paid ordinary shares following the exercise of options by SBC Global Investment Fund and an employee. This issuance, conducted without disclosure under specific sections of the Corporations Act, signifies a strategic move to enhance the company’s capital structure, potentially impacting its market positioning and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the quotation of 10,193,868 fully paid ordinary securities on the ASX, effective from September 11, 2025. This move is part of their strategic efforts to enhance liquidity and strengthen their financial position, potentially impacting their market presence and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced a new application for the quotation of 15,000,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, indicating strategic financial maneuvers that could enhance the company’s market presence and liquidity.
Lumos Diagnostics has signed a second distribution agreement for its FebriDx® test in Australia and New Zealand with Amtech, part of YesGroup. This partnership, alongside an existing agreement with Henry Schein, aims to expand the accessibility of FebriDx®, a rapid test that differentiates between bacterial and viral infections, thereby supporting informed clinical decisions and reducing unnecessary antibiotic use.
Lumos Diagnostics has secured a A$5.0 million loan facility with major shareholders Tenmile Ventures and Ryder Capital, providing financial flexibility as it seeks a CLIA waiver from the U.S. FDA for its FebriDx® test. This agreement replaces a previous convertible note arrangement and aims to support the company’s strategic goals while minimizing equity dilution, highlighting the ongoing commitment of its shareholders.
Lumos Diagnostics Holdings Ltd has issued 140,527 fully paid ordinary shares following the exercise of unquoted options by its employees. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating transparency and adherence to regulatory standards.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 140,527 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 3, 2025. This move signifies the company’s ongoing efforts to strengthen its market presence and enhance shareholder value, potentially impacting its financial standing and market positioning positively.
The earnings call for Lumos Diagnostics Holdings Ltd. painted a mixed picture, showcasing significant achievements in revenue growth and the Data Center segment, while also highlighting challenges in the gaming sector and the China market. This dual sentiment reflects the company’s current position in the market, with both promising opportunities and notable hurdles.
Lumos Diagnostics Holdings Ltd has issued 7,000,000 fully paid ordinary shares following the exercise of options by SBC Global Investment Fund. This issuance was conducted without investor disclosure under the Corporations Act, and the company confirms compliance with relevant legal provisions. This move reflects Lumos’s ongoing efforts to strengthen its financial position and enhance its market presence in the diagnostic technology sector.
Lumos Diagnostics Holdings Ltd. has announced the issuance of 7,000,000 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) under the code LDX. This move is part of the company’s strategy to strengthen its financial position and support its growth initiatives in the competitive diagnostics market.
Lumos Diagnostics has secured a follow-on contract with Aptatek Biosciences to advance the development of an in-home monitoring device for phenylketonuria (PKU), a rare genetic disorder. The contract, valued at $1.5 million, will see Lumos enhance the device’s design and conduct verification studies, with the project expected to commence in September 2025. This collaboration underscores Lumos’ expertise in diagnostic technologies and its role in potentially transforming PKU management, offering significant implications for patients and stakeholders in the healthcare sector.
Lumos Diagnostics Holdings Ltd. has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical study aimed at expanding the use of its FebriDx® diagnostic test to pediatric patients aged 2-12 years in CLIA-waived settings. This study, supported by a $6.198 million funding package from BARDA, is expected to significantly increase Lumos’ market reach by potentially expanding its U.S. total addressable market 15-fold to over $1 billion, providing access to 270,000 clinical sites and covering 80 million annual acute respiratory consultations.
Lumos Diagnostics Holdings Ltd. has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and proper management oversight.
Lumos Diagnostics Holdings Ltd. reported a revenue increase of 11.4% to US$12.4 million for the year ending June 30, 2025. Despite this growth, the company experienced a reduced loss of US$7.183 million, down 16.4% from the previous year, indicating efforts to improve financial performance. The report highlights a material uncertainty regarding the company’s ability to continue as a going concern, which may impact stakeholder confidence.
Lumos Diagnostics Holdings Ltd has issued 5,000,000 fully paid ordinary shares following the exercise of options by SBC Global Investment Funds. This issuance was conducted without investor disclosure under specific provisions of the Corporations Act. The company is preparing its annual report and planning a pediatric study for its FebriDx product, with ongoing discussions for potential non-dilutive funding.
Lumos Diagnostics Holdings Ltd. announced the issuance of 5,000,000 ordinary fully paid securities on August 26, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market position and offering new opportunities for stakeholders.
Lumos Diagnostics Holdings Ltd, a leader in rapid diagnostic technologies, announced it will release its FY25 financial results on August 28, 2025, followed by an investor briefing webinar on September 3, 2025. The briefing will provide an overview of the results and business updates, potentially impacting stakeholders by offering insights into the company’s operational and industry positioning.
Lumos Diagnostics has submitted a CLIA waiver application to the U.S. FDA for its FebriDx® test, which distinguishes between bacterial and non-bacterial respiratory infections. The submission follows successful clinical trials and triggers significant milestone payments from BARDA and PHASE Scientific. If granted, the waiver could expand Lumos’s U.S. market opportunity fifteen-fold to over $1 billion, enhancing its industry positioning and stakeholder value.
Lumos Diagnostics has partnered with PRO-spectus to enhance market access and reimbursement for its FebriDx® test in the US. This collaboration aims to secure coverage from private insurance payors, which dominate the US health insurance market, thereby increasing patient access to FebriDx®. The partnership will provide strategic and operational services to healthcare providers, facilitating reimbursement and adoption of FebriDx®, ultimately improving patient outcomes and addressing antimicrobial resistance.
Lumos Diagnostics has secured a waiver from the ASX Listing Rule 10.1, allowing it to grant a first-ranking general security over its assets without shareholder approval, facilitating a conditional secured loan facility of A$5.0 million from Tenmile Ventures and Ryder Capital. This financial arrangement, which includes a 12-month term with an optional extension, is poised to enhance Lumos’s operational flexibility and financial stability, potentially impacting its market positioning and stakeholder interests positively.